Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Squamous Cell Carcinoma 1

Interventions

Rituximab 32Cyclophosphamide 28Lenalidomide 19Prednisone 16Doxorubicin 16Vincristine 14Etoposide 11CT-P10 11Gemcitabine 9polatuzumab vedotin 8Oxaliplatin 7ibrutinib 6glofitamab 6fludarabine 6acalabrutinib 6Magnetic Resonance Spectroscopy 6Ifosfamide 6Carboplatin 6tafasitamab 5prednylidene 5pembrolizumab 5obinutuzumab 5deltacortene 5Specimen Handling 5R-CHOP protocol 5Nivolumab 5Biopsy 5venetoclax 4fludarabine phosphate 4selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Combined Modality Therapy × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡